Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022)
• By Region- North America, Europe, APAC and RoW
• By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan
• Company Analysis
(c) AZOTH Analytics
February 2018
Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) Scope of the Study g
Country Coverage
By Type- Therapeutics and Vaccine
Regional Coverage
By End Users- Male and Female
Product Coverage
Regional Coverage
Country Coverage
Company Coverage
USA Canada
North America
U.K.
Europe
Germany
Asia-Pacific Global Hepatitis B virus Treatment
France
ROW
China
Market Historical (2012-2016), By
Japan
Value
India
Global Hepatitis B virus Treatment
Merck and Co Gilead Sciences Novartis AG GlaxoSmithKline, plc Hoffmann- La Roche Bristol-Myers Squibb
Market Forecast (2017-2022), By Value Global Hepatitis B virus Treatment Market, By Type (2012-2022), By Value Global Hepatitis B virus Treatment Market, By End User (2012-2022), By Value
Hepatitis B virus
Hepatitis B virus
Treatment Market, By
Treatment Market, By
Type (2012-2022), By
Type (2012-2022), By
Value
Value
Hepatitis B virus
Hepatitis B virus
Treatment Market, By
Treatment Market, By
End User (2012-2022),
End User (2012-2022),
By Value
By Value
(c) AZOTH Analytics
Product Benchmarking Policy and Regulatory Landscape Financial Analysis Sales EBITDA PAT PBT Business Strategy
2
Table of Content S.No
Particulars
Page No.
1.
Research Methodology
23
2.
Executive Summary
24
3.
Strategic Recommendation
25
3.1
Asia Pacific Region to witness the fastest growth for Hepatitis B market in the forecast period
26
3.2
Therapeutic segment witnessing fastest growth
27
4.
Hepatitis B Treatment Market: Product Outlook
28
5.
Global Hepatitis B Treatment Market: Growth and Forecast
33
5.1
Global Hepatitis B Treatment Market, By Value (2012-2016)
34
5.2
Global Hepatitis B Treatment Market, By Value (2017-2022)
37
5.3
Global Hepatitis B Treatment Market - By Type, By Value
38
5.3.1
Global Hepatitis B Treatment Market, By Value, % (2016)
38
5.3.2
Global Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
39
5.4
5.5
Global Hepatitis B Treatment Market, By Type, By Value (2012-2022)
40
5.4.1
Therapeutics, By Value (2012-2022)
40
5.4.2
Vaccines, By Value (2012-2022)
40
Global Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
42
5.5.1
Male, By Value (2012-2022)
42
5.5.2
Female, By Value (2012-2022)
42
(c) AZOTH Analytics
3
Table of Content S.No
6.
Particulars
North America Hepatitis B Treatment Market: Growth and Forecast
Page No.
47
6.1
North America Hepatitis B Treatment Market, By Value (2012-2016)
48
6.2
North America Hepatitis B Treatment Market, By Value (2017-2022)
48
6.3
North America Hepatitis B Treatment Market - By Type, By Value
51
6.3.1
North America Hepatitis B Treatment Market, By Value, % (2016)
51
6.3.2
North America Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
52
6.4
6.5
6.6
North America Hepatitis B Treatment Market, By Type, By Value (2012-2022)
53
6.4.1
Therapeutics, By Value (2012-2022)
53
6.4.2
Vaccines, By Value (2012-2022)
53
North America Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
54
6.5.1
Male, By Value (2012-2022)
54
6.5.2
Female, By Value (2012-2022)
54
North America Hepatitis B Treatment Market: Country Analysis (U.S., Canada)
55
6.6.1
North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
55
6.6.2
North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
55
(c) AZOTH Analytics
4
Table of Content S. No
Particulars 6.7
6.8
6.9
6.10
6.11
6.12
U.S. Hepatitis B Treatment Market: Growth and Forecast
Page No. 57
6.7.1
U.S. Hepatitis B Treatment Market, By Value (2012-2016)
58
6.7.2
U.S. Hepatitis B Treatment Market, By Value (2017-2022)
58
U.S. Hepatitis B Treatment Market - By Type, By Value
62
6.8.1
Therapeutics, By Value (2012-2022)
62
6.8.2
Vaccines, By Value (2012-2022)
62
U.S. Hepatitis B Treatment Market - By End-User, By Value
63
6.9.1
Male, By Value (2012-2022)
63
6.9.2
Female, By Value (2012-2022)
63
Canada Hepatitis B Treatment Market: Growth and Forecast
65
6.10.1
Canada Hepatitis B Treatment Market, By Value (2012-2016)
66
6.10.2
Canada Hepatitis B Treatment Market, By Value (2017-2022)
66
Canada Hepatitis B Treatment Market - By Type, By Value
69
6.11.1
Therapeutics, By Value (2012-2022)
69
6.11.2
Vaccines, By Value (2012-2022)
69
Canada Hepatitis B Treatment Market - By End-User, By Value
70
6.12.1
Male, By Value (2012-2022)
70
6.12.2
Female, By Value (2012-2022)
70
(c) AZOTH Analytics
5
Table of Content S.No 7.
Particulars Europe Hepatitis B Treatment Market: Growth and Forecast
Page No. 71
7.1
Europe Hepatitis B Treatment Market, By Value (2012-2016)
72
7.2
Europe Hepatitis B Treatment Market, By Value (2017-2022)
72
7.3
Europe Hepatitis B Treatment Market - By Type, By Value
75
7.3.1
Europe Hepatitis B Treatment Market, By Value, % (2016)
75
7.3.2
Europe Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
76
7.4
7.5
Europe Hepatitis B Treatment Market, By Type, By Value (2012-2022)
77
7.4.1
Therapeutics, By Value (2012-2022)
77
7.4.2
Vaccines, By Value (2012-2022)
77
Europe Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
78
7.5.1
Male, By Value (2012-2022)
78
7.5.2
Female, By Value (2012-2022)
78
(c) AZOTH Analytics
6
Table of Content S. No
Particulars
7.6
7.7
7.8
7.9
7.10
Europe Hepatitis B Treatment Market: Country Analysis (U.K., Germany, France)
Page No.
79
7.6.1
Europe Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
79
7.6.2
Europe Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
79
U.K. Hepatitis B Treatment Market: Growth and Forecast
81
7.7.1
U.K. Hepatitis B Treatment Market, By Value (2012-2016)
82
7.7.2
U.K. Hepatitis B Treatment Market, By Value (2017-2022)
82
U.K. Hepatitis B Treatment Market - By Type, By Value
86
7.8.1
Therapeutics, By Value (2012-2022)
86
7.8.2
Vaccines, By Value (2012-2022)
86
U.K. Hepatitis B Treatment Market - By End-User, By Value
87
7.9.1
Male, By Value (2012-2022)
87
7.9.2
Female, By Value (2012-2022)
87
Germany Hepatitis B Treatment Market: Growth and Forecast
88
7.10.1
Germany Hepatitis B Treatment Market, By Value (2012-2016)
89
7.10.2
Germany Hepatitis B Treatment Market, By Value (2017-2022)
89
(c) AZOTH Analytics
7
Table of Content S. No
Particulars
7.11
7.12
7.13
7.14
7.15
Page No.
Germany Hepatitis B Treatment Market - By Type, By Value
92
7.11.1
Therapeutics, By Value (2012-2022)
92
7.11.2
Vaccines, By Value (2012-2022)
92
Germany Hepatitis B Treatment Market - By End-User, By Value
93
7.12.1
Male, By Value (2012-2022)
93
7.12.2
Female, By Value (2012-2022)
93
France Hepatitis B Treatment Market: Growth and Forecast
94
7.13.1
France Hepatitis B Treatment Market, By Value (2012-2016)
95
7.13.2
France Hepatitis B Treatment Market, By Value (2017-2022)
95
France Hepatitis B Treatment Market - By Type, By Value
98
7.14.1
Therapeutics, By Value (2012-2022)
98
7.14.2
Vaccines, By Value (2012-2022)
98
France Hepatitis B Treatment Market - By End-User, By Value
99
7.15.1
Male, By Value (2012-2022)
99
7.15.2
Female, By Value (2012-2022)
99
(c) AZOTH Analytics
8
Table of Content S.No
8.
Particulars
Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast
Page No.
100
8.1
Asia-Pacific Hepatitis B Treatment Market, By Value (2012-2016)
101
8.2
Asia-Pacific Hepatitis B Treatment Market, By Value (2017-2022)
101
8.3
Asia-Pacific Hepatitis B Treatment Market - By Type, By Value
103
8.3.1
Asia-Pacific Hepatitis B Treatment Market, By Value, % (2016)
103
8.3.2
Asia-Pacific Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
104
8.4
8.5
8.6
Asia-Pacific Hepatitis B Treatment Market, By Type, By Value (2012-2022)
105
8.4.1
Therapeutics, By Value (2012-2022)
105
8.4.2
Vaccines, By Value (2012-2022)
105
Asia-Pacific Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
106
8.5.1
Male, By Value (2012-2022)
106
8.5.2
Female, By Value (2012-2022)
106
Asia-Pacific Hepatitis B Treatment Market: Country Analysis (Japan, China, India)
(c) AZOTH Analytics
107
9
Table of Content S. No
Particulars
8.7
8.8
8.9
8.10
Page No.
8.6.1
Asia-Pacific Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
107
8.6.2
Asia-Pacific Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
107
Japan Hepatitis B Treatment Market: Growth and Forecast
109
8.7.1
Japan Hepatitis B Treatment Market, By Value (2012-2016)
110
8.7.2
Japan Hepatitis B Treatment Market, By Value (2017-2022)
110
Japan Hepatitis B Treatment Market - By Type, By Value
113
8.8.1
Therapeutics, By Value (2012-2022)
113
8.8.2
Vaccines, By Value (2012-2022)
113
Japan Hepatitis B Treatment Market - By End-User, By Value
114
8.9.1
Male, By Value (2012-2022)
114
8.9.2
Female, By Value (2012-2022)
114
China Hepatitis B Treatment Market: Growth and Forecast
115
8.10.1
China Hepatitis B Treatment Market, By Value (2012-2016)
116
8.10.2
China Hepatitis B Treatment Market, By Value (2017-2022)
116
(c) AZOTH Analytics
10
Table of Content S. No
Particulars
8.11
8.12
8.13
8.14
8.15
Page No.
China Hepatitis B Treatment Market - By Type, By Value
119
8.11.1
Therapeutics, By Value (2012-2022)
119
8.11.2
Vaccines, By Value (2012-2022)
119
China Hepatitis B Treatment Market - By End-User, By Value
120
8.12.1
Male, By Value (2012-2022)
120
8.12.2
Female, By Value (2012-2022)
120
India Hepatitis B Treatment Market: Growth and Forecast
122
8.13.1
India Hepatitis B Treatment Market, By Value (2012-2016)
123
8.13.2
India Hepatitis B Treatment Market, By Value (2017-2022)
123
India Hepatitis B Treatment Market - By Type, By Value
126
8.14.1
Therapeutics, By Value (2012-2022)
126
8.14.2
Vaccines, By Value (2012-2022)
126
India Hepatitis B Treatment Market - By End-User, By Value
127
8.15.1
Male, By Value (2012-2022)
127
8.15.2
Female, By Value (2012-2022)
127
(c) AZOTH Analytics
11
Table of Content S. No
9.
10.
Particulars
ROW Hepatitis B Treatment Market: Growth and Forecast
Page No.
128
9.1
ROW Hepatitis B Treatment Market, By Value (2012-2016)
129
9.2
ROW Hepatitis B Treatment Market, By Value (2017-2022)
129
Market Dynamics 10.1 10.2 10.3
132
Increasing prevalence of Liver diseases due to Hepatitis B Increasing awareness about the Hepatitis B & HBV Rising healthcare expenditure worldwide
134 135 136
11.
Market Restraints
137
12.
SWOT Analysis – Hepatitis B Treatment Market
141
13.
Porter’s Five Forces Analysis
143
14.
Policy and Regulations
145
15.
Global Hepatitis B Drugs Pipeline
153
16.
Global Hepatitis B Treatment Market - Competitive Landscape
159
(c) AZOTH Analytics
12
Table of Content S. No
17.
Particulars
Company Profile 17.1
17.2
17.3
17.4
17.5
17.6
17.7
18.
Page No.
161 162
Merck and Co
165
Gilead Sciences
167
Novartis AG
169
GlaxoSmithKline, plc
172
F.Hoffmann- La Roche
175
Bristol-Myers Squibb
179
AbbVie Inc
About US
181
(c) AZOTH Analytics
13
List of Figures Figure No.
Figure Title
Page No.
Figure 1:
Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million)
34
Figure 2:
Number of patients with Hepatitis B Virus (HBsAg) infection by WHO region, 2015 (In Million)
35
Figure 3:
Global Healthcare Expenditure, 2012-2016 (In Trillion)
36
Figure 4:
Global Hepatitis B Treatment Market Size, By Value, 2017-2022 (USD Million)
37
Figure 5:
Global Hepatitis B Treatment Market Size, By Type, 2016 (%)
38
Figure 6:
Global Hepatitis B Treatment Market Size, By Type, 2022 (%)
39
Figure 7:
Global Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
40
Figure 8:
Global Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
42
Figure 9:
Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
43
Figure 10:
Global Sales of Viread, By Value, 2015-2016 (USD Million)
43
Figure 11:
Global Hepatitis B Treatment Market Size, By Region, 2016 (%)
45
Figure 12:
Global Hepatitis B Treatment Market Size, By Region, 2022 (%)
46
Figure 13:
North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
48
Figure 14:
North America GDP, 2012-2015 (USD Trillion)
49
Figure 15:
North America GDP, By Select Country, 2016 (USD Trillion)
49
Figure 16:
Population aged 65 & above, 2012-2016 (% of total)
50
Figure 17:
North America Hepatitis B Treatment Market Size, By Type, 2016 (%)
51
Figure 18:
North America Hepatitis B Treatment Market Size, By Type, 2022 (%)
52
Figure 19:
North America Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
53
(c) AZOTH Analytics
14
List of Figures Figure No.
Figure Title
Page No.
Figure 20:
North America Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
54
Figure 21:
North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
55
Figure 22:
North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
55
Figure 23:
U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
58
Figure 24:
U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
60
Figure 25:
Reported acute (new) cases of Hepatitis B Virus in U.S., (2012-2015)
60
Figure 26:
Incidences rate of acute Hepatitis B in U.S., By sex (2012-2015)
60
Figure 27:
Incidence of acute Hepatitis B in U.S., By age group, (2012-2015)
61
Figure 28:
U.S. Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
62
Figure 29:
U.S. Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
63
Figure 30:
Market Share of HBV approved Drugs in U.S., 2016 (% Share)
64
Figure 31:
Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
66
Figure 32:
Canada Per Capita Healthcare Expenditure, 2012-2016 (In USD)
67
Figure 33:
Canada Life Expectancy at birth rate (Years), 2012-2015
67
Figure 34:
Prevalence of Hepatitis B in Canada, (Patients per 100,000 (2012-2016)
67
Figure 35:
Number of Hepatitis B Patients, Canada, (2013-2016)
67
Figure 36:
Prevalence of Hepatitis B among Male population, Canada, (Patients per 100,000) (2012-2016)
68
Figure 37:
Prevalence of Hepatitis B among Female population, Canada, (Patients per 100,000) (2012-2016)
68
Figure 38:
Canada Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
69
Figure 39:
Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
70
(c) AZOTH Analytics
15
List of Figures Figure No.
Figure Title
Page No.
Figure 40:
Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
72
Figure 41:
European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
73
Figure 42:
European Union Life Expectancy at birth rate (Years), 2012-2015
73
Figure 43:
Reported Hepatitis B Cases, Number & Rate per 100,000 populations, EU/EEA, 2012-2015
73
Figure 44:
Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
74
Figure 45:
Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
74
Figure 46:
Europe Hepatitis B Treatment Market Size, By Type, 2016 (%)
75
Figure 47:
Europe Hepatitis B Treatment Market Size, By Type, 2022 (%)
76
Figure 48:
Europe Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
77
Figure 49:
Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
78
Figure 50:
Europe Hepatitis B Treatment, Country Share, 2016 (% of Total)
79
Figure 51:
Europe Hepatitis B Treatment, Country Share, 2022 (% of Total)
79
Figure 52:
U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
82
Figure 53:
U.K. Population 65 Years & Above (% of Total), 2012-2016
84
Figure 54:
U.K. Life Expectancy at birth rate (Years), 2012-2015
84
Figure 55:
U.K. Women Population, 2012-2016
84
Figure 56:
U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
84
Figure 57:
Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
85
Figure 58:
Number of Hepatitis B Patients, (2013-2016)
85
Figure 59:
Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
85
Figure 60:
Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
85
(c) AZOTH Analytics
16
List of Figures Figure No.
Figure Title
Page No.
Figure 61:
U.K. Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
86
Figure 62:
U.K. Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
87
Figure 63:
Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
89
Figure 64:
Germany Population 65 Years & Above (% of Total), 2012-2016
90
Figure 65:
Germany Life Expectancy at birth rate (Years), 2012-2015
90
Figure 66:
Germany Women Population, 2012-2016
90
Figure 67:
Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
90
Figure 68:
Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
91
Figure 69:
Number of Hepatitis B Patients, (2013-2016)
91
Figure 70:
Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
91
Figure 71:
Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
91
Figure 72:
Germany Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
92
Figure 73:
Germany Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
93
Figure 74:
France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
95
Figure 75:
France Population 65 Years & Above (% of Total), 2012-2016
96
Figure 76:
France Life Expectancy at birth rate (Years), 2012-2015
96
Figure 77:
France Women Population, 2012-2016
96
Figure 78:
France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
96
Figure 79:
Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
97
Figure 80:
Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
97
(c) AZOTH Analytics
17
List of Figures Figure No.
Figure Title
Page No.
Figure 81:
Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
97
Figure 82:
France Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
98
Figure 83:
France Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
99
Figure 84:
Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
101
Figure 85:
Mortality due to Viral Hepatitis in South-East Asia region, 2015
102
Figure 86:
Asia-Pacific Hepatitis B Treatment Size, By Type, 2016 (%)
103
Figure 87:
Asia-Pacific Hepatitis B Drug Market Size, By Type, 2022 (%)
104
Figure 88:
Asia-pacific Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
105
Figure 89:
Asia-Pacific Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
106
Figure 90:
Asia-Pacific Hepatitis B Treatment, Country Share, 2016 (% of Total)
107
Figure 91:
Asia-Pacific Hepatitis B Treatment, Country Share, 2022 (% of Total)
107
Figure 92:
Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
110
Figure 93:
Japan Population 65 Years & Above (% of Total), 2012-2016
111
Figure 94:
Japan Life Expectancy at birth rate (Years), 2012-2015
111
Figure 95:
Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
111
Figure 96:
Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
112
Figure 97:
Number of Hepatitis B Patients, 2013-2016)
112
Figure 98:
Prevalence of Hepatitis B among Male population (Patients per 100,000 (2012-2016)
112
Figure 99:
Prevalence of Hepatitis B among Female population (Patients per 100,000 (2012-2016)
112
Japan Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
113
Figure 100:
(c) AZOTH Analytics
18
List of Figures Figure No.
Figure Title
Page No.
Figure 101:
Japan Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
114
Figure 102:
China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
116
Figure 103:
China Population 65 Years & Above (% of Total), 2012-2016
118
Figure 104:
China Life Expectancy at birth rate (Years), 2012-2015
118
Figure 105:
China Women Population, 2012-2016
118
Figure 106:
China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
118
Figure 107:
Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
119
Figure 108:
Number of Hepatitis B Patients, 2013-2016)
119
Figure 109:
Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
119
Figure 110:
Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
119
Figure 111:
China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
120
Figure 112:
China Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
121
Figure 113:
India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
123
Figure 114:
India Population 65 Years & Above (% of Total), 2012-2016
124
Figure 115:
India Life Expectancy at birth rate (Years), 2012-2015
124
Figure 116:
India Women Population, 2012-2016
124
Figure 117:
India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
124
Figure 118:
Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
125
Figure 119:
Number of Hepatitis B Patients, 2013-2016)
125
Figure 120:
Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
125
(c) AZOTH Analytics
19
List of Figures Figure No.
Figure Title
Page No.
Figure 121:
Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
125
Figure 122:
India Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
126
Figure 123:
India Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
127
Figure 124:
ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
129
Figure 125:
Prevalence of Hepatitis B in Brazil (Patients per 100,000 (2012-2016)
130
Figure 126:
Number of Hepatitis B Patients in Brazil, (2013-2016)
130
Figure 127:
Prevalence of Hepatitis B among Male population, in Brazil (Patients per 100,000) (2012-2016)
130
Figure 128:
Prevalence of Hepatitis B among Female population in Brazil (Patients per 100,000) (2012-2016)
130
Figure 129:
Prevalence of Hepatitis B in South Africa (Patients per 100,000 (2012-2016)
131
Figure 130:
Number of Hepatitis B Patients in South Africa, (2013-2016)
131
Figure 131:
Prevalence of Hepatitis B among Male population, in South Africa (Patients per 100,000) (2012-2016)
131
Figure 132:
Prevalence of Hepatitis B among Female population (Patients per 100,000), in South Africa (2012-2016)
131
Figure 133:
Global Healthcare Expenditure, 2012-2016 (In Trillion)
136
Figure 134:
Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
159
Figure 135:
Global Sales of Viread, By, Region, By Value, 2015-2016 (USD Million)
159
Figure 136:
Merck & Co., Net Sales, 2012-2016 (In million USD)
163
Figure 137:
Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
163
Figure 138:
Merck & Co., Net Sales, By Geographic Location, % Share 2016
163
Figure 139:
Merck & Co., Net Revenue, By Business Segment, % Share 2016
163
Figure 140:
Gilead Sciences Annual Revenue, 2014-2016 (USD Million)
166
(c) AZOTH Analytics
20
List of Figures Figure No.
Figure Title
Figure 141:
Gilead Sciences HBV Product Sales, 2014-2016 (USD Million)
166
Figure 142:
Gilead Sciences Revenue by Geographical, 2016 (%)
166
Figure 143:
Gilead Sciences Product Sales, 2016 (%)
166
Figure 144:
Novartis Annual Revenue, 2014-2016 (USD Million)
168
Figure 145:
Innovative Medicine net Sales, By Business Unit 2016 (%)
168
Figure 146:
Novartis Sales, By Region, 2016 (%)
168
Figure 147:
Novartis Sales, By Segment 2016 (%)
168
Figure 148:
GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
170
Figure 149:
Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
170
Figure 150:
Glaxosmithkline Sales, By Region, 2016 (%)
170
Figure 151:
Glaxosmithkline, Sales, By Segment 2016 (%)
170
Figure 152:
F. Hoffmann-La Roche Ltd Annual Revenue, 2014-2016 (USD Million)
173
Figure 153:
F. Hoffmann-La Roche Ltd Segmental Break Up, By Revenue, By Business Division, 2016 (%)
173
Figure 154:
F. Hoffmann-La Roche Ltd Geographical Break Up, By Revenue, 2016 (%)
173
Figure 155:
Bristol-Myers Squibb Company Annual Revenue, 2014-2016 (USD Million)
176
Figure 156:
Bristol-Myers Squibb Company Segmental Break Up, By Revenue, By Products, 2016 (%)
176
Figure 157:
Bristol-Myers Squibb Company Geographical Break Up, By Revenue, 2016 (%)
176
Figure 158:
Baraclude (entecavir), Annual Revenue, 2014-2016 (USD Million)
177
(c) AZOTH Analytics
Page No.
21
List of Figures Figure No.
Figure Title
Page No.
Figure 159:
Baraclude (entecavir), Segmental Break Up, By geographical segment, 2016 (%)
177
Figure 160:
AbbVie Revenue, Segmental Break Up, 2016
180
Figure 161:
AbbVie Revenue, Geographical Break Up, 2016
180
Table A:
Causes of Hepatitis B
29
Table B:
HBV Approved Therapies
31
Table C:
Globally Approved HBV Monovalent Vaccines
32
Table D:
Compounds in development for chronic Hepatitis B
(c) AZOTH Analytics
154
22
Research Methodology For our study on Global Hepatitis B Treatment Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts
across the value chain of Hepatitis B Treatment Market. Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of various other end-user sectors. Market sizing and growth in the forecast period (2017-2022) is estimated through product mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.
Report Focus: Hepatitis B Treatment Market - By Type – Therapeutics, Vaccine - By Region- North America, Europe, APAC and ROW - By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan
Company Analysis
Companies Contacted: GlaxoSmithKline Pharmaceuticals Ltd, Mylan Laboratories India Pvt Ltd
(c) AZOTH Analytics
23
Global Hepatitis B Treatment Market – Sizing and Growth High prevalence of Hepatitis B, improving access to diagnosis coupled with growing efforts to reduce large disease burden due to HBV infection is propelling the global market growth rate Figure : Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million) CAGR 2012-2016 Hepatitis B: xxxx%;
2012
2013
2014
2015
2016
Source: Azoth Analytics Estimates Xxxxx Xxxxx Xxxxx Xxxxx xxxxx
(c) AZOTH Analytics
24
Global Hepatitis B Treatment Market - Regional Analysis In the forecast period, North America is anticipated to hold it’s leading position in the market. However, Asia Pacific region is expected to grow at the highest pace.
Key Drivers
Figure : Global Hepatitis B Treatment Market Size, By Region, 2022 (%) Xxxxx xxxxx North America
Europe
Xxxxx xxxxx
Asia-Pacific
ROW
Xxxxx xxxxx
Source: Azoth Analytics Estimates
(c) AZOTH Analytics
25
North America Hepatitis B Treatment Market- By Country Share
Figure : North America Hepatitis B Treatment Market,
Figure : North America Hepatitis B Treatment Market,
Country Share, 2016 (% of Total)
Country Share, 2022 (% of Total)
Source: Azoth Analytics Estimates
United States
United States
Canada
Canada
Source: Azoth Analytics Estimates
(c) AZOTH Analytics
26
Europe Hepatitis B Treatment Market- By End-User, By Value Figure : Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
2012
CAGR 2012-2016
CAGR 2017-2022
Male: xx%; Female: xx%
Male: xx%; Female: xx%
2013
2014
2015
2016 2017 2018 Source: Azoth Analytics Estimates
2019
2020
2021
2022
Xxxxx Xxxxx Xxxxx Xxxxx Xxxxxx xxxxxx
(c) AZOTH Analytics
27
China Hepatitis B Treatment Market - By Type, By Value Figure : China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) CAGR 2012-2016
CAGR 2017-2022
Therapeutics: xx%; Vaccines: xx%
Therapeutics: xx%; Vaccines: xx%
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Source: Azoth Analytics Estimates Xxxxx Xxxxx Xxxxx Xxxxx
Xxxxx xxxxx
(c) AZOTH Analytics
28
About Azoth Analytics Pvt Ltd.
Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).
Related Reports: Global Oxygen Therapy Equipment Market - Analysis By Product, Portability, Application, Region, Country: Opportunities and Forecast (2017- 2022) -- By Product (Oxygen Concentrators, Liquid Oxygen Devices and Oxygen Cylinders), By Portability (Stationary, Portable
Devices), By Application (COPD, Asthma, Cystic Fibrosis, Respiratory Distress Syndrome) Global Industrial X-Ray Inspection System Market - By Imaging Technique, By Digital Imaging Type, By Digital Radiography Type, By End User, By Region, By Country (2017-2022) -- By Imaging Technique (Film Based, Digital), By Digital Imaging Type (Digital Radiography, Computed Tomography), By Digital Radiography Type (Direct Digital, Computed Radiography)
Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for
any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.
(c) AZOTH Analytics
29